OS Fund

Ginkgo Bioworks is a biotechnology company that designs custom microbes for a variety of applications, including pharmaceuticals, agriculture, and industrial processes.

Atomwise uses machine learning to discover novel, drug-like molecules for drug development, focusing on immune and inflammatory diseases.

Synthego is a biotechnology company that specializes in CRISPR gene editing and molecular diagnostics, providing innovative solutions for genetic engineering and diagnostics.

Arzeda is a protein design company that creates new designer proteins and enzymes to address challenges in food production, nutrition, and sustainable materials. They utilize Intelligent Protein Design Technology, combining physics-based design and AI to innovate across various industries.

Pivot Bio develops crop nutrition technologies that harness the power of nature to deliver nitrogen to plants, enabling microbes to convert atmospheric nitrogen and provide it to crops throughout the growing season. Their solutions aim to improve profitability, predictability, safety, and sustainability for farmers.

Just Egg is a plant-based alternative to traditional eggs, offered by Justforall.com. It features vegan recipes, including scrambles and frittatas.

Verge Genomics is pioneering an AI-powered drug discovery platform that utilizes human genomics and machine learning to develop new drugs for complex diseases, focusing on conditions like ALS, Parkinson's Disease, and Frontotemporal Dementia.

OpsReady is a work completion software for industrial operations, focusing on outcomes and streamlining processes through an all-in-one mobile application.

Elysium Health translates scientific advancements in aging research into accessible health products and technologies, focusing on supplements that promote healthy aging.

Lygos is an industrial biotechnology company developing biobased sustainable solutions to improve everyday products. Our technology platform enables better economics and unlocks the power of organic acids specialty chemicals, enabling our partners to offer sustainable alternatives to legacy petroleum-based plastics, fragrances, home and personal care products, and more.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Writes first institutional checks ($500k–$5M) at earliest stages for compute-applied chemistry and biology ventures (therapeutics, industrial biotech, climate, materials), led by an advanced-degree scientific team.

Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.

Exclusive synthetic biology investor focused on companies replacing industrial inputs with biology-based alternatives, led by a UCSF-trained PhD cell biologist offering deep research expertise and global Latin America–Europe reach.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.